New osteoarthritis medications

There are several new osteoarthritis (OA) medications that have been approved or are in development. Here are some examples:

  1. Olorinab (Qlatsel): An oral medication that targets the cannabinoid receptor type 2 (CB2) to reduce inflammation and pain. It was approved by the FDA in 2020.
  2. Zilretta (Triamcinolone acetonide extended-release injectable suspension): A long-acting corticosteroid injection that provides sustained relief from OA pain for up to 12 weeks. It was approved by the FDA in 2018.
  3. Xiaflex (Collagenase clostridium histolyticum): A biologic medication that breaks down collagen in the joint, reducing pain and improving function. It was approved by the FDA in 2013 for the treatment of Dupuytren's contracture, but is also being studied for OA.
  4. Sodium oxybate (Xyrem): A medication that has been approved for the treatment of narcolepsy, but is also being studied for its potential to reduce OA pain.
  5. Bimekizumab (UCB): A biologic medication that targets the IL-17A and IL-17F cytokines, which are involved in the inflammatory process of OA. It is currently in Phase III clinical trials.
  6. Tanezumab (Pfizer): A monoclonal antibody that targets nerve growth factor (NGF), which is involved in pain signaling. It is currently in Phase III clinical trials.
  7. GSK2894512 (GlaxoSmithKline): A small molecule medication that targets the P2X7 receptor, which is involved in the inflammatory process of OA. It is currently in Phase II clinical trials.
  8. LX2761 (Lixivaptan): A small molecule medication that targets the vasopressin receptor, which is involved in the inflammatory process of OA. It is currently in Phase II clinical trials.
  9. APD371 (Aurinia Pharmaceuticals): A small molecule medication that targets the cannabinoid receptor type 1 (CB1) to reduce inflammation and pain. It is currently in Phase II clinical trials.
  10. GSK3228835 (GlaxoSmithKline): A small molecule medication that targets the PPARγ receptor, which is involved in the inflammatory process of OA. It is currently in Phase I clinical trials.

It's important to note that while these medications show promise, they are not yet widely available or approved for the treatment of OA. Additionally, the FDA approval process can take several years, and more research is needed to confirm their safety and efficacy.